Coherus Biosciences, which recently gained its first biosimilar approval for Udenyca, a pegfilgrastim biosimilar referencing Neulasta, has announced that it has signed a 340B prime vendor program contract with Apexus LLC.
Coherus Biosciences, which recently gained its first biosimilar approval for Udenyca, a pegfilgrastim biosimilar referencing Neulasta, has announced that it has signed a 340B prime vendor program contract with Apexus LLC.
Apexus is the Health Resources and Services Administration’s designated prime vendor for the 340B Drug Pricing Program, under which it contracts with nearly all of the 340B-eligible covered entities, and the 340B channel accounts for approximately 35% of the reference pegfilgrastim units sold in the United States.
“Apexus is pleased to be one of Coherus BioSciences’ first partners in the launch of Udenyca,” said Chris Hatwig, president of Apexus, in a statement. “We look forward to working with Coherus in optimizing biosimilar use with this new agreement for Udenyca and to lowering drug pricing while improving patient access.”
Coherus also revealed that it has received a Q code from CMS for Udenyca, and that the code will be active in time for the January launch of Udenyca. With the Q code in place, it will now apply to CMS for transitional pass-through payment status for hospital outpatient settings.
“We continue to progress toward achievement of a robust UDENYCA™ launch on January 3, 2019,” said Denny Lanfear, CEO of Coherus. “The Apexus agreement and [Q code] issuance are [2] important initial components for bringing choice and significant value to patients, payors and providers across the [United States].”
Coherus’ biosimilar was approved in November, making it the second pegfilgrastim biosimilar to gain the FDA’s authorization. First approved was Mylan and Biocon’s Fulphila, which has already launched in the United States. Coherus has said that it will match Mylan’s product on price by discounting its biosimilar by 33% relative to the reference product. Both Udenyca and Fulphila will carry list prices of $4175 per unit.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.